Ra Medical Systems has filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Ra Medical Systems has applied to list its common stock on the New York Stock Exchange (NYSE) under the ticker symbol “RMED.”
Piper Jaffray & Co. and Cantor Fitzgerald & Co. will act as lead joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. will act as lead manager and Nomura Securities International, Inc. will act as co-manager for the offering.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering, when available, may be obtained from: Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at [email protected]; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, NY 10022, or by email at [email protected].
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
In May 2017, the US Food and Drug Administration (FDA) granted market clearance to Ra Medical Systems for the company’s Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) system. The system is intended to deliver a safer, faster and cheaper solution to peripheral arterial disease treatment than the market otherwise offers.
